The filing is a routine advance notice of a small insider sale by a director. No material impact is expected. Monitor for any subsequent Form 4 filings to confirm execution, but this is not a signal of insider concern.
LGND drugs
LGND drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Oct 30 $322.75entry
- T+1 · 15d ago −4.87%α −4.39% · $307.02
- T+5 · 11d ago −5.13%α −2.42% · $306.20
- T+11 · todayOpen
- T+20 · in 13d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Jason Aryeh filed a Form 144 notice of intent to sell 202 shares of Ligand Pharmaceuticals common stock, with an estimated market value of approximately $64,738 based on the filing date. The proposed sale is small relative to the company's $6.4B market cap and the director's holdings, and the filing is a routine advance notice of a planned trade.
Key Facts
- Director Jason Aryeh filed Form 144 on 2026-10-30 for a proposed sale of 202 shares of Ligand Pharmaceuticals common stock.
- The estimated value of the proposed sale is $64,738.
- The shares were acquired on 03/13/2019 via an open market purchase.
- The proposed sale is to be executed through Charles Schwab & Co., Inc. on Nasdaq.
- The sale represents a negligible fraction of the company's $6.4B market cap.
Financial Impact
Proposed sale of 202 shares valued at $64,738, a de minimis amount relative to the company's $6.4B market cap.
Risk Factors
- Form 144 is only an intent to sell; the sale may not be executed.
- No other insider selling patterns or context provided to suggest broader insider sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001949846-26-000627 |
| Document: 0001949846-26-000627-index.html | 0001949846-26-000627 |
| Document: 0001949846-26-000627.txt | 0001949846-26-000627 |
Track record
29 reports on LGND
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers